Evidence map›Paper›PMID 33216283›Full record

ArticleNeurotoxicity research2021

The Neuroprotective Effect of Mesna on Cisplatin-Induced Neurotoxicity: Behavioral, Electrophysiological, and Molecular Studies.

Hakimeh Saadati, Somayeh Noroozzadeh, Hedieh Esmaeili, Keyvan Amirshahrokhi, Javad Shadman, Ali Niapour

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Kinin BPharmaceutics · 2023
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hakimeh SaadatiDepartment of Physiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Somayeh Noroozzadeh *Department of Biochemistry, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Hedieh Esmaeili *Department of Biochemistry, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Keyvan AmirshahrokhiDepartment of Pharmacology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Javad ShadmanDepartment of Physiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Ali NiapourResearch Laboratory for Embryology and Stem Cells, Department of Anatomical Sciences, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran. a.niapour@arums.ac.ir.ORCID http://orcid.org/0000-0002-9013-4664
Ardabil University of Medical Sciences · IR

Funding

Ardabil University of Medical Sciences 9413
6 · The paper itself

Abstract

Peripheral neuropathy and cognitive impairments following cisplatin administration may interfere with the clinical usage of the drug. Mesna is a chemoprotective agent with anti-inflammatory and anti-oxidant effects. Our study aimed to investigate the protective effects of mesna against cisplatin-induced neurotoxicity. Neurotoxicity was induced by the administration of 2.5 mg/kg cisplatin twice a week for four consecutive weeks in male Wistar rats. The neuroprotective effect of mesna (150 mg/kg/day) was evaluated through behavioral, electrophysiological, and molecular studies. Cisplatin treatment caused passive avoidance memory impairment, increased anxiety-like behaviors, altered thermal sensitivity, and decreased muscle strength in a grip strength test. Our electrophysiological studies indicated that administration of cisplatin induced peripheral sensory neuropathy and decreased the amplitudes of the compound action potential of sensory nerves. Cisplatin administration increased MDA and 4-HNE levels and decreased anti-oxidant (SOD and GPx) enzymes. Proinflammatory cytokines (IL-1β and TNF-α) and metalloproteinase-2 and 9 (MMP-2/9) were increased by cisplatin treatment. Morphological alterations were observed in the dorsal root ganglion (DRG) of cisplatin-treated rats. Cognitive impairments, anxiety, muscle strength, and thermal sensitivity changes induced by cisplatin were improved with mesna treatment. The reduced conduction velocity in sensory nerves was recovered in the cisplatin + mesna group. Mesna partially alleviated redox imbalance, reduced the proinflammatory cytokines, and MMP-2/9 levels. Mesna administration also relieved the morphological changes in DRG of cisplatin-treated rats. In conclusion, our results revealed that mesna can alleviate cisplatin-induced central and peripheral nervous system toxicity. These results support the concept that chemotherapy-induced neuropathy can be partially inhibited via mesna.

Indexed as

AnimalsAntineoplastic AgentsCisplatinElectrophysiological PhenomenaInflammation MediatorsMaleMemory DisordersMesnaNeuroprotective AgentsOxidative StressProtective AgentsRatsRats, WistarAntineoplastic AgentsCisplatinInflammation MediatorsMesnaNeuroprotective AgentsProtective AgentsCisplatin-induced neuropathyDorsal root ganglionInflammationMesnaNerve conduction velocityOxidative stress

Identifiers

PMID33216283
OpenAlexW3104979374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.